Abstract
Fibrosis can lead to a broad range of diseases affecting essentially every organ. Thus, interventions targeting fibrosis are expected to have profound therapeutic effects. However, thus far there are no effective clinical treatments to specifically block fibrotic processes, underscoring the necessity of enhanced research efforts in this arena. The hallmark of vascular fibrotic disorders is extensive extracellular matrix remodeling primarily mediated by myofibroblasts. A prominent feature of the vasculature is that all three major constituent cell types, fibroblasts, smooth muscle cells, and endothelial cells, maintain phenotypic plasticity. In response to various fibrogenic stimuli, these vascular cells along with progenitor cells can transform into myofibroblasts or myofibroblast-like cells, collectively yet variably contributing to vascular fibrosis. As such, the vascular system provides useful models for studying fibrotic mechanisms. In this chapter, we focus on vascular fibrosis and associated diseases, providing an overview of the underlying cellular and molecular mechanisms and their multifaceted impacts on disease outcomes. Potential antifibrotic targets and the emerging importance of epigenetic regulators in the major vascular diseases are also discussed.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Benjamin EJ, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146–603.
Low Wang CC, et al. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus – mechanisms, management, and clinical considerations. Circulation. 2016;133(24):2459–502.
Roll S, et al. Dacron vs. PTFE as bypass materials in peripheral vascular surgery – systematic review and meta-analysis. BMC Surg. 2008;8:22.
McVicker BL, Bennett RG. Novel anti-fibrotic therapies. Front Pharmacol. 2017;8:318.
Lan TH, Huang XQ, Tan HM. Vascular fibrosis in atherosclerosis. Cardiovasc Pathol. 2013;22(5):401–7.
Zeisberg M, Kalluri R. Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. Am J Phys Cell Phys. 2013;304(3):C216–25.
Rockey DC, Bell PD, Hill JA. Fibrosis – a common pathway to organ injury and failure. N Engl J Med. 2015;373(1):96.
Nanthakumar CB, et al. Dissecting fibrosis: therapeutic insights from the small-molecule toolbox. Nat Rev Drug Discov. 2015;14(10):693–720.
Ruiz-Ortega M, et al. TGF-beta signaling in vascular fibrosis. Cardiovasc Res. 2007;74(2):196–206.
Goel SA, et al. Mechanisms of post-intervention arterial remodelling. Cardiovasc Res. 2012;96(3):363–71.
Otsuka F, et al. Pathology of coronary atherosclerosis and thrombosis. Cardiovasc Diagn Ther. 2016;6(4):396–408.
Glagov S, et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316(22):1371–5.
Katsuda S, Kaji T. Atherosclerosis and extracellular matrix. J Atheroscler Thromb. 2003;10(5):267–74.
Chung IM, et al. Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment. J Am Coll Cardiol. 2002;40(12):2072–81.
Pasterkamp G, de Kleijn DP, Borst C. Arterial remodeling in atherosclerosis, restenosis and after alteration of blood flow: potential mechanisms and clinical implications. Cardiovasc Res. 2000;45(4):843–52.
Hillis LD, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58(24):e123–210.
Kasapis C, Gurm HS. Current approach to the diagnosis and treatment of femoral-popliteal arterial disease. A systematic review. Curr Cardiol Rev. 2009;5(4):296–311.
Gloviczki P, et al. The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American venous forum. J Vasc Surg. 2011;53(5 Suppl):2S–48S.
Hess CN, et al. Saphenous vein graft failure after coronary artery bypass surgery: insights from PREVENT IV. Circulation. 2014;130(17):1445–51.
Lu DY, et al. Vein graft adaptation and fistula maturation in the arterial environment. J Surg Res. 2014;188(1):162–73.
Owens CD, et al. Vein graft failure. J Vasc Surg. 2015;61(1):203–16.
Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25(5):932–43.
Kassab GS. Biomechanics of the cardiovascular system: the aorta as an illustratory example. J R Soc Interface. 2006;3(11):719–40.
Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens. 2003;21(1):3–12.
Stratton MS, McKinsey TA. Epigenetic regulation of cardiac fibrosis. J Mol Cell Cardiol. 2016;92:206–13.
Phan SH. Biology of fibroblasts and myofibroblasts. Proc Am Thorac Soc. 2008;5(3):334–7.
Emerson GG, Segal SS. Electrical coupling between endothelial cells and smooth muscle cells in hamster feed arteries: role in vasomotor control. Circ Res. 2000;87(6):474–9.
Kendall RT, Feghali-Bostwick CA. Fibroblasts in fibrosis: novel roles and mediators. Front Pharmacol. 2014;5:123.
Sartore S, et al. Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: from innocent bystander to active participant. Circ Res. 2001;89(12):1111–21.
Si Y, et al. Protein kinase C-delta mediates adventitial cell migration through regulation of monocyte chemoattractant protein-1 expression in a rat angioplasty model. Arterioscler Thromb Vasc Biol. 2012;32(4):943–54.
Krishnan P, et al. Enhanced neointimal fibroblast, myofibroblast content and altered extracellular matrix composition: implications in the progression of human peripheral artery restenosis. Atherosclerosis. 2016;251:226–33.
Durgin BG, et al. Smooth muscle cell-specific deletion of Col15a1 unexpectedly leads to impaired development of advanced atherosclerotic lesions. Am J Physiol Heart Circ Physiol. 2017;312(5):H943–58.
Douillet CD, et al. Mechanisms by which bradykinin promotes fibrosis in vascular smooth muscle cells: role of TGF-beta and MAPK. Am J Physiol Heart Circ Physiol. 2000;279(6):H2829–37.
Bennett MR, Sinha S, Owens GK. Vascular smooth muscle cells in atherosclerosis. Circ Res. 2016;118(4):692–702.
MacLeod DC, et al. Proliferation and extracellular matrix synthesis of smooth muscle cells cultured from human coronary atherosclerotic and restenotic lesions. J Am Coll Cardiol. 1994;23(1):59–65.
Gan Q, et al. Smooth muscle cells and myofibroblasts use distinct transcriptional mechanisms for smooth muscle alpha-actin expression. Circ Res. 2007;101(9):883–92.
Baum J, Duffy HS. Fibroblasts and myofibroblasts: what are we talking about? J Cardiovasc Pharmacol. 2011;57(4):376–9.
Chappell J, et al. Extensive proliferation of a subset of differentiated, yet plastic, medial vascular smooth muscle cells contributes to neointimal formation in mouse injury and atherosclerosis models. Circ Res. 2016;119(12):1313–23.
Gomez D, Owens GK. Reconciling smooth muscle cell oligoclonality and proliferative capacity in experimental atherosclerosis. Circ Res. 2016;119(12):1262–4.
Lin F, Wang N, Zhang TC. The role of endothelial-mesenchymal transition in development and pathological process. IUBMB Life. 2012;64(9):717–23.
Chen PY, et al. Endothelial-to-mesenchymal transition drives atherosclerosis progression. J Clin Invest. 2015;125(12):4514–28.
Cooley BC, et al. TGF-beta signaling mediates endothelial-to-mesenchymal transition (EndMT) during vein graft remodeling. Sci Transl Med. 2014;6(227):227ra34.
Chen PY, et al. Fibroblast growth factor receptor 1 is a key inhibitor of TGFbeta signaling in the endothelium. Sci Signal. 2014;7(344):ra90.
Hoshino A, et al. Human vascular adventitial fibroblasts contain mesenchymal stem/progenitor cells. Biochem Biophys Res Commun. 2008;368(2):305–10.
Chen D, et al. Fibrocytes mediate intimal hyperplasia post-vascular injury and are regulated by two tissue factor-dependent mechanisms. J Thromb Haemost. 2013;11(5):963–74.
Hu Y, et al. Abundant progenitor cells in the adventitia contribute to atherosclerosis of vein grafts in ApoE-deficient mice. J Clin Invest. 2004;113(9):1258–65.
Chen Y, et al. Adventitial stem cells in vein grafts display multilineage potential that contributes to neointimal formation. Arterioscler Thromb Vasc Biol. 2013;33(8):1844–51.
Wu J, et al. Origin of matrix-producing cells that contribute to aortic fibrosis in hypertension. Hypertension. 2016;67(2):461–8.
Shankman LS, et al. KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis. Nat Med. 2015;21(6):628–37.
Di Carlo SE, Peduto L. The perivascular origin of pathological fibroblasts. J Clin Invest. 2018;128(1):54–63.
Jonsson S, et al. Increased levels of leukocyte-derived MMP-9 in patients with stable angina pectoris. PLoS One. 2011;6(4):e19340.
Reilkoff RA, Bucala R, Herzog EL. Fibrocytes: emerging effector cells in chronic inflammation. Nat Rev Immunol. 2011;11(6):427–35.
Wermuth PJ, Jimenez SA. The significance of macrophage polarization subtypes for animal models of tissue fibrosis and human fibrotic diseases. Clin Transl Med. 2015;4:2.
Orbe J, et al. Different expression of MMPs/TIMP-1 in human atherosclerotic lesions. Relation to plaque features and vascular bed. Atherosclerosis. 2003;170(2):269–76.
Madhur MS, et al. Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol. 2011;31(7):1565–72.
Ma T, et al. Th17 cells and IL-17 are involved in the disruption of vulnerable plaques triggered by short-term combination stimulation in apolipoprotein E-knockout mice. Cell Mol Immunol. 2013;10(4):338–48.
Danzaki K, et al. Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2012;32(2):273–80.
Cox TR, Erler JT. Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. Dis Model Mech. 2011;4(2):165–78.
Maurice P, et al. Elastin fragmentation and atherosclerosis progression: the elastokine concept. Trends Cardiovasc Med. 2013;23(6):211–21.
Morimoto S, et al. Fragmentation of internal elastic lamina and spread of smooth muscle cell proliferation induced by percutaneous transluminal coronary angioplasty. Jpn Circ J. 1993;57(5):388–94.
Wong CY, et al. Elastin is a key regulator of outward remodeling in arteriovenous fistulas. Eur J Vasc Endovasc Surg. 2015;49(4):480–6.
Xu J, Shi GP. Vascular wall extracellular matrix proteins and vascular diseases. Biochim Biophys Acta. 2014;1842(11):2106–19.
Goel SA, et al. Preferential secretion of collagen type 3 versus type 1 from adventitial fibroblasts stimulated by TGF-beta/Smad3-treated medial smooth muscle cells. Cell Signal. 2013;25(4):955–60.
Nave AH, et al. Lysyl oxidases play a causal role in vascular remodeling in clinical and experimental pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol. 2014;34(7):1446–58.
Wallner K, et al. Adventitial remodeling after angioplasty is associated with expression of tenascin mRNA by adventitial myofibroblasts. J Am Coll Cardiol. 2001;37(2):655–61.
Giachelli CM, et al. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest. 1993;92(4):1686–96.
Lindner V, et al. Vascular injury induces expression of periostin: implications for vascular cell differentiation and migration. Arterioscler Thromb Vasc Biol. 2005;25(1):77–83.
Chajara A, et al. Effect of aging on neointima formation and hyaluronan, hyaluronidase and hyaluronectin production in injured rat aorta. Atherosclerosis. 1998;138(1):53–64.
Gaggar A, et al. The role of matrix metalloproteinases in cystic fibrosis lung disease. Eur Respir J. 2011;38(3):721–7.
George SJ, et al. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation. 2000;101(3):296–304.
Papazafiropoulou A, Tentolouris N. Matrix metalloproteinases and cardiovascular diseases. Hippokratia. 2009;13(2):76–82.
Cardellini M, et al. TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1. Diabetes. 2009;58(10):2396–401.
Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev. 2005;85(1):1–31.
Takayanagi T, et al. Vascular ADAM17 as a novel therapeutic target in mediating cardiovascular hypertrophy and perivascular fibrosis induced by angiotensin II. Hypertension. 2016;68(4):949–55.
Cheng XW, et al. Cysteine protease cathepsins in atherosclerosis-based vascular disease and its complications. Hypertension. 2011;58(6):978–86.
Lutgens SP, et al. Cathepsin cysteine proteases in cardiovascular disease. FASEB J. 2007;21(12):3029–41.
Oksala N, et al. ADAM-9, ADAM-15, and ADAM-17 are upregulated in macrophages in advanced human atherosclerotic plaques in aorta and carotid and femoral arteries – Tampere vascular study. Ann Med. 2009;41(4):279–90.
Ashley EA, et al. Network analysis of human in-stent restenosis. Circulation. 2006;114(24):2644–54.
Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-beta: the master regulator of fibrosis. Nat Rev Nephrol. 2016;12(6):325–38.
Goumans MJ, Liu Z, ten Dijke P. TGF-beta signaling in vascular biology and dysfunction. Cell Res. 2009;19(1):116–27.
Pohlers D, et al. TGF-beta and fibrosis in different organs – molecular pathway imprints. Biochim Biophys Acta. 2009;1792(8):746–56.
Thannickal VJ, et al. Myofibroblast differentiation by transforming growth factor-beta1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J Biol Chem. 2003;278(14):12384–9.
Shi X, et al. TGF-beta/Smad3 stimulates stem cell/developmental gene expression and vascular smooth muscle cell de-differentiation. PLoS One. 2014;9(4):e93995.
Zhu Y, et al. Restenosis inhibition and re-differentiation of TGFbeta/Smad3-activated smooth muscle cells by resveratrol. Sci Rep. 2017;7:41916.
Risinger GM Jr, et al. TGF-beta suppresses the upregulation of MMP-2 by vascular smooth muscle cells in response to PDGF-BB. Am J Phys Cell Phys. 2010;298(1):C191–201.
Kundi R, et al. Arterial gene transfer of the TGF-beta signalling protein Smad3 induces adaptive remodelling following angioplasty: a role for CTGF. Cardiovasc Res. 2009;84(2):326–35.
Rakugi H, et al. Induction of angiotensin converting enzyme in the neointima after vascular injury. Possible role in restenosis. J Clin Invest. 1994;93(1):339–46.
Krege JH, et al. Angiotensin-converting enzyme gene and atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17(7):1245–50.
Ford CM, Li S, Pickering JG. Angiotensin II stimulates collagen synthesis in human vascular smooth muscle cells. Involvement of the AT(1) receptor, transforming growth factor-beta, and tyrosine phosphorylation. Arterioscler Thromb Vasc Biol. 1999;19(8):1843–51.
Clempus RE, Griendling KK. Reactive oxygen species signaling in vascular smooth muscle cells. Cardiovasc Res. 2006;71(2):216–25.
Wynne BM, Chiao CW, Webb RC. Vascular smooth muscle cell signaling mechanisms for contraction to angiotensin II and endothelin-1. J Am Soc Hypertens. 2009;3(2):84–95.
Sriramula S, Francis J. Tumor necrosis factor – alpha is essential for angiotensin II-induced ventricular remodeling: role for oxidative stress. PLoS One. 2015;10(9):e0138372.
van Thiel BS, et al. The renin-angiotensin system and its involvement in vascular disease. Eur J Pharmacol. 2015;763(Pt A):3–14.
Gerritsen KG, et al. Plasma CTGF is independently related to an increased risk of cardiovascular events and mortality in patients with atherosclerotic disease: the SMART study. Growth Factors. 2016;34(3–4):149–58.
Leeuwis JW, et al. Connective tissue growth factor is associated with a stable atherosclerotic plaque phenotype and is involved in plaque stabilization after stroke. Stroke. 2010;41(12):2979–81.
Jiang Z, et al. TGF-beta- and CTGF-mediated fibroblast recruitment influences early outward vein graft remodeling. Am J Physiol Heart Circ Physiol. 2007;293(1):H482–8.
Rectenwald JE, et al. Direct evidence for cytokine involvement in neointimal hyperplasia. Circulation. 2000;102(14):1697–702.
Jiang Z, et al. Tumor necrosis factor-alpha and the early vein graft. J Vasc Surg. 2007;45(1):169–76.
Wang W, et al. SIRT1 inhibits TNF-alpha-induced apoptosis of vascular adventitial fibroblasts partly through the deacetylation of FoxO1. Apoptosis. 2013;18(6):689–701.
Ali MS, et al. TNF-alpha induces phenotypic modulation in cerebral vascular smooth muscle cells: implications for cerebral aneurysm pathology. J Cereb Blood Flow Metab. 2013;33(10):1564–73.
Zhang H, et al. Role of TNF-alpha in vascular dysfunction. Clin Sci (Lond). 2009;116(3):219–30.
Fang L, Murphy AJ, Dart AM. A clinical perspective of anti-fibrotic therapies for cardiovascular disease. Front Pharmacol. 2017;8:186.
Janic M, Lunder M, Sabovic M. Arterial stiffness and cardiovascular therapy. Biomed Res Int. 2014;2014:621437.
Tam LS, et al. Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis – a randomized trial. J Rheumatol. 2012;39(12):2267–75.
Di Micco P, et al. Intima-media thickness evolution after treatment with infliximab in patients with rheumatoid arthritis. Int J Gen Med. 2009;2:141–4.
Rosenbloom J, Mendoza FA, Jimenez SA. Strategies for anti-fibrotic therapies. Biochim Biophys Acta. 2013;1832(7):1088–103.
Chung IM, et al. Blockade of TGF-beta by catheter-based local intravascular gene delivery does not alter the in-stent neointimal response, but enhances inflammation in pig coronary arteries. Int J Cardiol. 2010;145(3):468–75.
Appleby CE, et al. Periluminal expression of a secreted transforming growth factor-beta type II receptor inhibits in-stent neointima formation following adenovirus-mediated stent-based intracoronary gene transfer. Hum Gene Ther. 2014;25(5):443–51.
Lipson KE, et al. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair. 2012;5(Suppl 1):S24.
West NE, et al. Nitric oxide synthase (nNOS) gene transfer modifies venous bypass graft remodeling: effects on vascular smooth muscle cell differentiation and superoxide production. Circulation. 2001;104(13):1526–32.
Nakao A, et al. Ex vivo carbon monoxide delivery inhibits intimal hyperplasia in arterialized vein grafts. Cardiovasc Res. 2011;89(2):457–63.
Rosenbaum MA, et al. Antioxidant therapy reverses impaired graft healing in hypercholesterolemic rabbits. J Vasc Surg. 2010;51(1):184–93.
Zhong L, et al. The anti-fibrotic effect of bone morphogenic protein-7(BMP-7) on liver fibrosis. Int J Med Sci. 2013;10(4):441–50.
Wang C, et al. The anti-fibrotic actions of relaxin are mediated through a NO-sGC-cGMP-dependent pathway in renal myofibroblasts in vitro and enhanced by the NO donor, Diethylamine NONOate. Front Pharmacol. 2016;7:91.
Brookes E, Shi Y. Diverse epigenetic mechanisms of human disease. Annu Rev Genet. 2014;48:237–68.
Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12(12):861–74.
Gao P, et al. Upregulation of MicroRNA-15a contributes to pathogenesis of abdominal aortic aneurysm (AAA) by modulating the expression of cyclin-dependent kinase inhibitor 2B (CDKN2B). Med Sci Monit. 2017;23:881–8.
Maegdefessel L, et al. MicroRNA-21 blocks abdominal aortic aneurysm development and nicotine-augmented expansion. Sci Transl Med. 2012;4(122):122ra22.
Maegdefessel L, et al. miR-24 limits aortic vascular inflammation and murine abdominal aneurysm development. Nat Commun. 2014;5:5214.
Boon RA, et al. MicroRNA-29 in aortic dilation: implications for aneurysm formation. Circ Res. 2011;109(10):1115–9.
Eken SM, et al. MicroRNA-210 enhances fibrous cap stability in advanced atherosclerotic lesions. Circ Res. 2017;120(4):633–44.
Ji R, et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ Res. 2007;100(11):1579–88.
Yang J, et al. MicroRNA-24 attenuates neointimal hyperplasia in the diabetic rat carotid artery injury model by inhibiting Wnt4 signaling pathway. Int J Mol Sci. 2016;17(6):765.
Lee J, et al. MicroRNA-29b inhibits migration and proliferation of vascular smooth muscle cells in neointimal formation. J Cell Biochem. 2015;116(4):598–608.
Cordes KR, et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature. 2009;460(7256):705–10.
Zheng L, et al. MicroRNA-155 regulates angiotensin II type 1 receptor expression and phenotypic differentiation in vascular adventitial fibroblasts. Biochem Biophys Res Commun. 2010;400(4):483–8.
Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev. 2011;25(10):1010–22.
Connelly JJ, et al. Epigenetic regulation of COL15A1 in smooth muscle cell replicative aging and atherosclerosis. Hum Mol Genet. 2013;22(25):5107–20.
Narayanan N, et al. Epigenetic regulation of aortic remodeling in hyperhomocysteinemia. FASEB J. 2014;28(8):3411–22.
Liu R, et al. Ten-eleven translocation-2 (TET2) is a master regulator of smooth muscle cell plasticity. Circulation. 2013;128(18):2047–57.
Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 2011;21(3):381–95.
Yoshida T, Owens GK. Molecular determinants of vascular smooth muscle cell diversity. Circ Res. 2005;96(3):280–91.
Hoeksema MA, et al. Targeting macrophage Histone deacetylase 3 stabilizes atherosclerotic lesions. EMBO Mol Med. 2014;6(9):1124–32.
Ding N, et al. BRD4 is a novel therapeutic target for liver fibrosis. Proc Natl Acad Sci U S A. 2015;112(51):15713–8.
Tang X, et al. BET bromodomain proteins mediate downstream signaling events following growth factor stimulation in human lung fibroblasts and are involved in bleomycin-induced pulmonary fibrosis. Mol Pharmacol. 2013;83(1):283–93.
Kumar K, et al. BET inhibitors block pancreatic stellate cell collagen I production and attenuate fibrosis in vivo. JCI Insight. 2017;2(3):e88032.
Anand P, et al. BET bromodomains mediate transcriptional pause release in heart failure. Cell. 2013;154(3):569–82.
Wang B, et al. BET Bromodomain blockade mitigates intimal hyperplasia in rat carotid arteries. EBioMedicine. 2015;2(11):1650–61.
Acknowledgments
This work was supported by NIH grants R01 HL133665 (to L-WG), R01HL143469 and R01HL129785 (both to KCK and L-WG), and R01HL-068673 (to KCK), and AHA predoctoral fellowship awards (17PRE33670865 to MZ and 16PRE30160010 to BW).
We thank Dr. Matthew Stratton in the Davis Heart and Lung Research Institute of the Ohio State University for informative discussion and proofreading.
Conflict of Interest
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Zhang, M., Wang, B., Kent, K.C., Guo, LW. (2019). Vascular Fibrosis and Disease. In: Willis, M., Yates, C., Schisler, J. (eds) Fibrosis in Disease . Molecular and Translational Medicine. Humana Press, Cham. https://doi.org/10.1007/978-3-319-98143-7_14
Download citation
DOI: https://doi.org/10.1007/978-3-319-98143-7_14
Published:
Publisher Name: Humana Press, Cham
Print ISBN: 978-3-319-98142-0
Online ISBN: 978-3-319-98143-7
eBook Packages: MedicineMedicine (R0)